Beta-blockers may improve survival in epithelial ovarian cancer
the ONA take:
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer, according to a new study published today in the journal Cancer.
For the study, researchers from The University of Texas MD Anderson Cancer Center in Houston, TX, retrospectively analyzed the medical records of 1,425 women with epithelial ovarian cancer treated between 2000 and 2010 in order to evaluate the impact of beta-blocker use during chemotherapy on overall survival.
Among 269 patients who received beta-blocker therapy, about 72% received beta-1 adrenergic receptor selective agents like atenolol, metoprolol, and bisoprolol, while the rest received nonselective beta-blockers, such as propranolol, carvedilol, and labetalol.
Results showed that median overall survival for beta-blocker and non-beta-blocker users was 47.8 months and 42 months, respectively.
Researchers found that patients receiving selective beta-1 blockers had a median overall survival of 94.9 months vs 38 months for those receiving non-selective beta antagonists.
The researchers note, however, that further studies are required before beta-blockers are recommended as adjuvant therapy in patients with ovarian cancer undergoing surgery.
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|